Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAL101553 |
Synonyms | |
Therapy Description |
Lisavanbulin (BAL101553) is the prodrug of the microtubule inhibiting drug BAL27862, which may result in decreased growth and migration of tumor cells (PMID: 27540016). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAL101553 | Lisavanbulin | Antimicrotubule Agent 14 | Lisavanbulin (BAL101553) is the prodrug of the microtubule inhibiting drug BAL27862, which may result in decreased growth and migration of tumor cells (PMID: 27540016). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03250299 | Phase I | BAL101553 | Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | Terminated | USA | 0 |
NCT02490800 | Phase Ib/II | BAL101553 | Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma | Completed | GBR | DEU | CHE | BEL | 0 |